1. Record Nr. UNIORUON00042173

Autore	NAUMANN, Rudolf
Titolo	Architektur kleinasiens von ihren anfangen bis zum ende der hethitischen zeit / Rudolf Naumann
Pubbl/distr/stampa	Tubingen, : Ernst Wasmuth, 1971
ISBN	38-03-01014-4
Descrizione fisica	XIII, 508 p. : ill. ; 26 c
Classificazione	VOA XI
Soggetti	ARCHITETTURA - VICINO ORIENTE ANTICO
Lingua di pubblicazione	Tedesco
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	In testa al front. Deutsches Archaologisches Institut

2. Record Nr. UNINA9910227348003321

Autore	Wilfredo Mellado
Titolo	Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
Pubbl/distr/stampa	Frontiers Media SA, 2017
Descrizione fisica	1 online resource (116 p.)
Collana	Frontiers Research Topics
Soggetti	Neurosciences
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	Pioneering studies conducted in the 1980's laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and

oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly established myelin as a key factor in regenerative failure. Mechanistically, it has been shown that MAG, Nogo, and OMgp mediate inhibition by binding to either Nogo receptor (NgR) or paired immunoglobulin receptor B (PirB), and initiating a signaling cascade that culminates in the activation of RhoA. Since the discovery of these proteins, there has been tremendous interest in identifying compounds and molecular mechanisms that are capable of overcoming myelin-mediated inhibition. Many studies have focused on pharmacological antagonism of receptors and signaling intermediates, while others have sought to identify and enhance endogenous pro-regenerative pathways. The most notable example of the latter is the conditioning lesion effect, which led to the discovery of cyclic AMP's ability to overcome inhibition by MAG and myelin. Many of the agents tested in these studies have been shown to promote axonal regeneration in vivo, and this research topic allows researchers to share information about new treatments that have been developed in both academia and industry. As we look toward the future, it is becoming increasingly clear that reversal of myelin-mediated inhibition alone will not be sufficient to produce functional recovery from spinal cord injury, and that other factors, such as astroglial scarring, the expression of chondroitin sulfate proteoglycans, neuronal cell death, and lack of neurotrophic support, must also be taken into consideration. Combinatorial approaches therefore hold a great deal of promise, and we hope to initiate a dialogue on how stem cell transplantation, chondroitinase ABC, gene therapy, growth-promoting agents, and other methods can be combined to optimize functional recovery. We introduce this topic in honor of the life and work of Dr. Marie T. Filbin (1955-2014). Through these articles, we highlight past achievements in the field, novel findings, unanswered questions and innovative ideas that we hope will lead to new advances in axonal regeneration.

3.

Record Nr.	UNINA9910165046703321
Titolo	Contemporary issues in pharmaceutical patent law : setting the framework and exploring policy options / / edited by Bryan Mercurio and Daria Kim
Pubbl/distr/stampa	London ; ; New York : , : Routledge, , 2017
ISBN	1-315-67797-0 1-317-38978-6
Edizione	[1st ed.]
Descrizione fisica	1 online resource (258 pages) : illustrations, tables
Collana	Routledge Research in Intellectual Property
Altri autori (Persone)	KimDaria MercurioBryan
Disciplina	346.0486
Soggetti	Drugs Patent laws and legislation
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di contenuto	Part. I. Pharmaceutical patents and related types of protection -- Part. II. Balancing patent protection with available flexibilities -- Part. III. A broader view on incentives for pharmaceutical innovation.
Sommario/riassunto	This collection reflects on contemporary and contentious issues in international rulemaking in regards to pharmaceutical patent law. With chapters from both well-established and rising scholars, the collection contributes to the understanding of the regulatory framework governing pharmaceutical patents as an integrated discipline through the assessment of relevant laws, trends and policy options. Focusing on patent law and related pharmaceutical regulations, the collection addresses the pressing issues governments face in an attempt to resolve policy dilemmas involving competing interests, needs and objectives. The common theme running throughout the collection is the need for policy and law makers to think and act in a systemic manner and to be more reflective and responsive in finding new solutions within and outside the patent system to the long-standing problems as well as emerging challenges